

Notification HUM-7234

Category

HCPCS - Drugs & Biologicals

Topic

Rituximab, 10 mg, and its biosimilars – HCPCS codes J9312, Q5115, Q5119 and Q5123

What is changing? / Change Description:

We limit reimbursement of charges for rituximab, 10 mg, and its biosimilars to claims submitted with any of the following diagnoses:

- Acute lymphoblastic leukemia • ANCA-associated vasculitis
- Autoimmune hemolytic anemia
- Bullous pemphigoid • Burkitt lymphoma
- Castleman disease • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) cicatricial pemphigoid
- Diffuse large B-cell lymphoma
- Evans syndrome
- Follicular lymphoma
- Graft-versus-host disease
- Hairy cell leukemia • Hodgkin lymphoma immune (idiopathic) thrombocytopenic purpura
- Lupus nephritis
- Mantle cell lymphoma • Microscopic polyangiitis • Multiple sclerosis • Myasthenia gravis
- Nephritic syndrome • Neuromyelitis optica
- Non-Hodgkin lymphoma (B-cell lymphomas)
- Pemphigus vulgaris • Post-transplant lymphoproliferative disorder (PTLD)
- Rheumatoid arthritis
- Sjogren's syndrome • Systemic lupus erythematosus
- Thrombotic microangiopathy • Thrombotic thrombocytopenic purpura or Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma
- Wegener's granulomatosis

Language

English

Impacted Products

Medicaid – Louisiana

Why is Humana making this change? / Change Reason:

The limitations above are supported by the FDA-approved package insert and prescribing information and pharmaceutical compendia guidance for rituximab and its biosimilars.